SG10202003996YA - Humanized c5 and c3 animals - Google Patents

Humanized c5 and c3 animals

Info

Publication number
SG10202003996YA
SG10202003996YA SG10202003996YA SG10202003996YA SG10202003996YA SG 10202003996Y A SG10202003996Y A SG 10202003996YA SG 10202003996Y A SG10202003996Y A SG 10202003996YA SG 10202003996Y A SG10202003996Y A SG 10202003996YA SG 10202003996Y A SG10202003996Y A SG 10202003996YA
Authority
SG
Singapore
Prior art keywords
humanized
animals
Prior art date
Application number
SG10202003996YA
Inventor
Ying Hu
Adrianna Latuszek
Jingtai Cao
Alexander Mujica
Stanley Wiegand
John Mcwhirter
Andrew Murphy
Lynn Macdonald
Meagher Karolina
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG10202003996YA publication Critical patent/SG10202003996YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
SG10202003996YA 2014-05-05 2015-05-04 Humanized c5 and c3 animals SG10202003996YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461988581P 2014-05-05 2014-05-05
US201462067836P 2014-10-23 2014-10-23

Publications (1)

Publication Number Publication Date
SG10202003996YA true SG10202003996YA (en) 2020-06-29

Family

ID=53177902

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202003996YA SG10202003996YA (en) 2014-05-05 2015-05-04 Humanized c5 and c3 animals
SG11201608696RA SG11201608696RA (en) 2014-05-05 2015-05-04 Humanized c5 and c3 animals

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201608696RA SG11201608696RA (en) 2014-05-05 2015-05-04 Humanized c5 and c3 animals

Country Status (15)

Country Link
US (5) US9795121B2 (en)
EP (3) EP3636073B1 (en)
JP (1) JP6598798B2 (en)
KR (1) KR102461511B1 (en)
CN (1) CN106659146B (en)
AU (1) AU2015256299C1 (en)
BR (1) BR112016025751A2 (en)
CA (2) CA2946412C (en)
ES (2) ES2968749T3 (en)
IL (1) IL248481B (en)
MA (1) MA51519A (en)
MX (2) MX386644B (en)
RU (2) RU2713327C2 (en)
SG (2) SG10202003996YA (en)
WO (1) WO2015171523A1 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (en) 2013-03-15 2015-09-30 Regeneron Pharma SERUM FREE CELL CULTIVATION MEDIA
SG10202003996YA (en) 2014-05-05 2020-06-29 Regeneron Pharma Humanized c5 and c3 animals
NO2785538T3 (en) 2014-05-07 2018-08-04
TW202440904A (en) 2015-08-04 2024-10-16 美商再生元醫藥公司 Taurine supplemented cell culture medium and methods of use
WO2017132155A1 (en) * 2016-01-25 2017-08-03 President And Fellows Of Harvard College Methods and compositions for detecting and treating schizophrenia
ES2984352T3 (en) 2016-06-14 2024-10-29 Regeneron Pharma Anti-C5 antibodies and their uses
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
US10765762B2 (en) 2017-02-27 2020-09-08 Regeneron Pharmaceuticals, Inc. Humanized model of kidney and liver disorders
KR102659791B1 (en) 2017-07-06 2024-04-23 리제너론 파마슈티칼스 인코포레이티드 Cell culture process to make glycoproteins
MX394999B (en) * 2017-09-29 2025-03-24 Regeneron Pharma Non-human animals comprising a humanized
PT3687287T (en) * 2017-09-29 2023-11-03 Regeneron Pharma Non-human animals expressing humanized c1q complex
CN107736281A (en) * 2017-09-29 2018-02-27 中国水产科学研究院珠江水产研究所 A kind of method that pond culture mandarin fish parasite is prevented and treated using probiotics fermention soy sauce residues
MA51147A (en) 2017-12-13 2021-03-24 Regeneron Pharma ANTI-C5 ANTIBODY ASSOCIATIONS AND ASSOCIATED USES
BR112020010615A2 (en) 2017-12-22 2020-10-27 Regeneron Pharmaceuticals, Inc. protein pharmaceutical product, method and system for characterizing protein pharmaceutical product and low molecular weight impurities, method for producing an antibody, antibody, and, method and system uses
CN111655722A (en) 2018-01-31 2020-09-11 瑞泽恩制药公司 Systems and Methods for Characterizing Drug Product Impurities
TW202311746A (en) 2018-02-02 2023-03-16 美商再生元醫藥公司 System and method for characterizing protein dimerization
MX2020008988A (en) 2018-02-28 2020-09-28 Regeneron Pharma Systems and methods for identifying viral contaminants.
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
CA3089655C (en) 2018-03-19 2026-01-20 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
WO2019195136A1 (en) 2018-04-03 2019-10-10 Ngm Biopharmaceuticals, Inc. C3-binding agents and methods of use thereof
TW202016125A (en) 2018-05-10 2020-05-01 美商再生元醫藥公司 Systems and methods for quantifying and modifying protein viscosity
IL278267B2 (en) 2018-07-16 2025-02-01 Regeneron Pharma Non-human animal models of ditra disease and uses thereof
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
AU2019333047A1 (en) 2018-08-30 2020-12-03 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
CA3111396A1 (en) * 2018-09-06 2020-03-12 The Trustees Of The University Of Pennsylvania Humanized anti-c5 antibodies and uses thereof
ES2942024T3 (en) 2019-01-16 2023-05-29 Regeneron Pharma Methods to characterize disulfide bonds
ES2966625T3 (en) 2019-04-04 2024-04-23 Regeneron Pharma Rodents comprising a humanized coagulation factor 12 locus
JP7654564B2 (en) * 2019-04-24 2025-04-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Bifunctional humanized anti-C5 antibodies and factor H fusion proteins thereof and uses thereof
EP3969908A1 (en) 2019-05-13 2022-03-23 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
US11891618B2 (en) 2019-06-04 2024-02-06 Regeneron Pharmaceuticals, Inc. Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
US11622547B2 (en) 2019-06-07 2023-04-11 Regeneran Pharmaceuticals, Inc. Genetically modified mouse that expresses human albumin
EP4653865A3 (en) 2019-09-24 2026-02-18 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
WO2021108548A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
MX2022008973A (en) 2020-01-21 2022-08-11 Regeneron Pharma DEGLYCOSYLATION METHODS FOR ELECTROPHORESIS OF GLYCOSYLATED PROTEINS.
AU2021332355A1 (en) 2020-08-31 2023-03-23 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
AU2021352420A1 (en) 2020-10-01 2023-04-27 Regeneron Pharmaceuticals, Inc. Rodent animals expressing human cr1
WO2022115588A1 (en) 2020-11-25 2022-06-02 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
JP2024500409A (en) 2020-12-17 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Preparation of protein-encapsulated microgels
KR20230134117A (en) 2021-01-20 2023-09-20 리제너론 파마슈티칼스 인코포레이티드 Methods for improving protein titer in cell culture
IL305156A (en) 2021-03-03 2023-10-01 Regeneron Pharma Systems and methods for quantifying and changing protein viscosity
BR112023018665A2 (en) 2021-03-26 2023-10-03 Regeneron Pharma METHODS AND SYSTEMS FOR DEVELOPING MIXING PROTOCOLS
EP4348234B1 (en) 2021-06-01 2026-04-08 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US20230077710A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
JP2024531800A (en) 2021-09-20 2024-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Methods for controlling antibody heterogeneity
CA3230985A1 (en) 2021-10-07 2023-04-13 Ross BROWNE Ph meter calibration and correction
WO2023059800A2 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
CA3236367A1 (en) 2021-10-26 2023-05-04 Michelle Lafond Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
EP4423271A2 (en) 2021-10-28 2024-09-04 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
IL315548A (en) 2022-03-18 2024-11-01 Regeneron Pharma Methods and systems for analyzing polypeptide variants
EP4634659A1 (en) 2022-12-16 2025-10-22 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
WO2024158961A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
EP4704808A1 (en) 2023-05-01 2026-03-11 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol
TW202528736A (en) 2023-09-08 2025-07-16 美商再生元醫藥公司 Methods and systems for assessing chromatographic column integrity
WO2025064403A2 (en) 2023-09-18 2025-03-27 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
CN121925272A (en) 2023-09-29 2026-04-24 瑞泽恩制药公司 Lyophilization with controlled nucleation
WO2025085594A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
US20250145662A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025122669A1 (en) * 2023-12-05 2025-06-12 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized complement factor b gene
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
TW202602489A (en) 2024-03-15 2026-01-16 美商再生元醫藥公司 Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography
WO2026025028A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Methods of making ultra-high concentrated protein formulations using lyophilization
WO2026060350A1 (en) 2024-09-13 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
WO2026076201A2 (en) 2024-10-03 2026-04-09 Regeneron Pharmaceuticals, Inc. Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
WO2026080597A1 (en) 2024-10-08 2026-04-16 Regeneron Pharmaceuticals, Inc. Sustained delivery of biologics and non-aqueous manufacture of same

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984003506A1 (en) 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
GB2183661B (en) 1985-03-30 1989-06-28 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5266684A (en) 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5571689A (en) 1988-06-16 1996-11-05 Washington University Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US5770434A (en) 1990-09-28 1998-06-23 Ixsys Incorporated Soluble peptides having constrained, secondary conformation in solution and method of making same
WO1992009300A1 (en) 1990-11-21 1992-06-11 Iterex Pharmaceuticals Ltd. Partnership Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6166288A (en) * 1995-09-27 2000-12-26 Nextran Inc. Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor
GB9521943D0 (en) 1995-10-26 1996-01-03 Univ Hertfordshire Coded particles for process sequence tracking in combinatorial compound library preparation
ES2292236T3 (en) 1998-04-02 2008-03-01 Genentech, Inc. VARIATIONS OF ANTIBODIES AND THEIR FRAGMENTS.
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6280946B2 (en) 1998-08-07 2001-08-28 Boston Probes, Inc. PNA probes, probe sets, methods and kits pertaining to the universal detection of bacteria and eucarya
CA2355215A1 (en) 1998-12-28 2000-07-06 Jim Wells Identifying small organic molecule ligands for binding
WO2005060739A1 (en) 2003-12-24 2005-07-07 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
ES2432112T3 (en) 2004-02-10 2013-11-29 The Regents Of The University Of Colorado, A Body Corporate Inhibition of factor B, of the alternative complement pathway and related methods
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
US20090032592A1 (en) 2006-01-11 2009-02-05 Novo Nordisk A/S Spherical encoded beads
EP2254911B1 (en) * 2008-02-20 2015-11-25 Novo Nordisk A/S Humanized anti-c5ar antibodies
RU2425880C2 (en) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Method of producing transgene mice
PT2485583T (en) 2009-10-06 2016-09-22 Univ Yale Genetically modified mice and engraftment
MX350385B (en) 2011-02-15 2017-09-04 Regeneron Pharma MOUSES OF HUMANIZED M-CSF.
SI2770821T1 (en) 2011-10-28 2018-01-31 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
WO2013063556A1 (en) 2011-10-28 2013-05-02 Regeneron Pharmaceuticals, Inc. Humanized il-6 and il-6 receptor
US8962913B2 (en) * 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
IN2015DN02032A (en) 2012-09-07 2015-08-14 Univ Yale
CA2887706C (en) 2012-11-05 2022-08-02 Regeneron Pharmaceuticals Genetically modified non-human animals and methods of use thereof
PL2958937T3 (en) 2013-02-22 2019-01-31 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
ES2715949T3 (en) 2013-10-15 2019-06-07 Regeneron Pharma Animals with humanized IL-15
SG10201811701YA (en) 2013-11-19 2019-01-30 Regeneron Pharma Non-human animals having a humanized a proliferation-inducing ligand gene
SG10202003996YA (en) * 2014-05-05 2020-06-29 Regeneron Pharma Humanized c5 and c3 animals

Also Published As

Publication number Publication date
AU2015256299B2 (en) 2021-09-23
US10492477B2 (en) 2019-12-03
IL248481B (en) 2021-04-29
EP3636073C0 (en) 2023-11-15
JP2017514496A (en) 2017-06-08
IL248481A0 (en) 2016-12-29
US20200037587A1 (en) 2020-02-06
KR20170002472A (en) 2017-01-06
KR102461511B1 (en) 2022-11-01
EP4317445A2 (en) 2024-02-07
AU2015256299A1 (en) 2016-12-08
CN106659146B (en) 2020-06-23
NZ763860A (en) 2024-05-31
RU2713327C2 (en) 2020-02-04
ES2779070T3 (en) 2020-08-13
CN106659146A (en) 2017-05-10
CA2946412A1 (en) 2015-11-12
JP6598798B2 (en) 2019-10-30
US20180332833A1 (en) 2018-11-22
EP3142483A1 (en) 2017-03-22
WO2015171523A1 (en) 2015-11-12
MX2016014504A (en) 2017-05-23
EP3636073A1 (en) 2020-04-15
MX386644B (en) 2025-03-19
BR112016025751A2 (en) 2018-01-16
US20220132818A1 (en) 2022-05-05
RU2016146390A (en) 2018-06-06
MA51519A (en) 2020-11-11
CA3225091A1 (en) 2015-11-12
US9795121B2 (en) 2017-10-24
US11178860B2 (en) 2021-11-23
CA2946412C (en) 2024-02-27
NZ726602A (en) 2024-05-31
ES2968749T3 (en) 2024-05-13
AU2015256299C1 (en) 2022-01-06
US20150313194A1 (en) 2015-11-05
US10524458B2 (en) 2020-01-07
EP3636073B1 (en) 2023-11-15
EP3142483B1 (en) 2020-01-22
RU2020103811A (en) 2020-02-18
EP4317445A3 (en) 2024-05-15
US20170332611A1 (en) 2017-11-23
SG11201608696RA (en) 2016-11-29
RU2016146390A3 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
IL304841A (en) Humanized il-4 and il-4r animals
IL248481B (en) Humanized c5 and c3 animals
IL251537A0 (en) Humanized anti-ox40 antibodies and uses thereof
IL250461A0 (en) Anti-cll-1 antibodies and immunoconjugates
IL249188A0 (en) Anti-her2 glycoantibodies and uses thereof
IL252216A0 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
PL3215147T3 (en) Neuro-attenuating norketamine compounds and methods
IL252929B (en) Humanized anti-acth antibodies and use thereof
HUE046767T2 (en) Anti-ox40 antibodies and methods of use
SG11201700884TA (en) Fish trap
PT3101131T (en) Anti-transthyretin humanized antibody
IL251837A0 (en) Anti-endoglin antibodies and uses thereof
PT3101132T (en) Anti-transthyretin human antibody
IL251107A0 (en) Compounds and methods
PL3180356T3 (en) Human anti-fgfr4 antibody
ZA201702491B (en) Optimized braid construction
PL2905411T3 (en) Gate
GB201415250D0 (en) Compound and method
GB201409990D0 (en) Loungers for pets
PL3031357T3 (en) Pivotal fitting
GB201421735D0 (en) Humanized gut microbiota
GB201420773D0 (en) Compound and method
GB201400792D0 (en) Farming idea- Tri-culture farming/Duo-culture farming
GB201415254D0 (en) Compound and method
GB201415247D0 (en) Compound and method